Research programme: idiopathic pulmonary fibrosis therapeutic - Celdara Medical/Pulmatrix

Drug Profile

Research programme: idiopathic pulmonary fibrosis therapeutic - Celdara Medical/Pulmatrix

Alternative Names: CM Y JH01; CM-Y-JH01 dry powder - Celdara Medical/Pulmatrix

Latest Information Update: 16 Mar 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Celdara Medical; Pulmatrix
  • Developer Celdara Medical; Pulmatrix; University of Vermont
  • Class Biological factors; Biological proteins
  • Mechanism of Action Epithelial cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Idiopathic pulmonary fibrosis

Most Recent Events

  • 02 Oct 2015 Preclinical trials in Idiopathic pulmonary fibrosis in USA (Inhalation), before October 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top